Richard Eisenstadt
2019 - Neos Therapeutics
In 2019, Richard Eisenstadt earned a total compensation of $837K as Chief Financial Officer at Neos Therapeutics, which was about the same as previous year.
Compensation breakdown
| Bonus | $36,748 |
|---|---|
| Non-Equity Incentive Plan | $117,661 |
| Option Awards | $309,908 |
| Salary | $358,879 |
| Other | $13,835 |
| Total | $837,031 |
Eisenstadt received $358.9K in salary, accounting for 43% of the total pay in 2019.
Eisenstadt also received $36.7K in bonus, $117.7K in non-equity incentive plan, $309.9K in option awards and $13.8K in other compensation.
Rankings
In 2019, Richard Eisenstadt's compensation ranked 10,033rd out of 13,971 executives tracked by ExecPay. In other words, Eisenstadt earned more than 28.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 10,033 out of 13,971 | 28th |
Division Manufacturing | 4,056 out of 5,701 | 29th |
Major group Chemicals And Allied Products | 1,540 out of 2,200 | 30th |
Industry group Drugs | 1,318 out of 1,886 | 30th |
Industry Pharmaceutical Preparations | 981 out of 1,398 | 30th |
Source: SEC filing on April 21, 2020.
Eisenstadt's colleagues
We found two more compensation records of executives who worked with Richard Eisenstadt at Neos Therapeutics in 2019.
News
PharmAthene CEO Vipin Garg's 2022 pay rises 9% to $2.9M
August 16, 2023
PharmAthene CEO Vipin Garg's 2021 pay jumps 83% to $2.6M
August 16, 2022
AYTU BIOPHARMA CEO Joshua Disbrow's 2021 pay jumps 291% to $6.2M
April 7, 2022
Neos Therapeutics CEO Gerald McLaughlin's 2019 pay falls 56% to $1.4M
April 21, 2020
Neos Therapeutics CEO Gerald McLaughlin receives $3.2M in 2018
April 24, 2019